RiverVest
RiverVest is a venture capital firm which focuses on identifying and shaping early stage life science companies to create shareholder value.
Business Model:
Revenue: $5M
Employees: 51-200
Rankings
Industries / Tags:
Detailed RiverVest Information
Geographic Data
Address: 101 S Hanley Rd
City: Saint Louis
State: MO
Zip: 63105
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$963M
Social
Facebook
Twitter
Linkedin
Crunchbase
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
RiverVest is a venture capital firm which focuses on identifying and shaping early stage life science companies that creates shareholder values. Their team’s domain experience allows them to identify, find, and actively incubate promising life science companies in the medical device and biopharmaceutical industries. It provides practical advice and strategic leadership to help entrepreneurs drive early-stage companies forward. It also invests in selected later-stage life science companies to diversify risk and maximize portfolio returns. RiverVest is a U.S.-based company that was founded in 2000 by Jay W. Schmelter.
Contact Phone:
+13147266700
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 12/2020 | Reneo Pharmaceuticals | Series B | 0 |
| 6/2019 | InterVene | Series B | 0 |
| 11/2021 | Biolinq | Series B | 0 |
| 11/2012 | Smart Wires | Series A | 10M |
| 1/2017 | Adarza BioSystems | Series C | 17M |
| 9/2014 | Allakos | Series A | 10M |
| 5/2020 | Good Therapeutics | Series A | 0 |
| 10/2021 | Scout Bio | Series B | 0 |
| 1/2023 | Alleviant Medical | Venture Round | 0 |
| 10/2013 | Securus Medical Group | Series B | 0 |
| 10/2008 | Lutonix | Series B | 20M |
| 4/2021 | Arch Oncology | Series C | 0 |
| 9/2010 | Accumetrics | Venture Round | 0 |
| 10/2009 | Accumetrics | Series E | 0 |
| 8/2017 | Neuros Medical | Series A | 20M |
| 3/2019 | Arch Oncology | Series B | 0 |
| 11/2011 | Neuros Medical | Series A | - |
| 5/2020 | Amplyx Pharmaceuticals | Series C | 0 |
| 10/2003 | Salient Surgical Technologies | Series D | 0 |
| 7/2003 | Velocimed | Series C | 18M |
| 2/2021 | Xilio Therapeutics | Series C | 95M |
| 3/2019 | Scout Bio | Series B | 20M |
| 1/2013 | Tryton Medical | Unattributed | 24M |
| 9/2018 | OncoResponse | Series B | 40M |
| 10/2008 | MacroGenics | Series D | 25M |
| 9/2013 | Otonomy | Series C | 45.9M |
| 5/2021 | Sparrow Pharmaceuticals | Series A | 50M |
| 8/2017 | Venture Med Group | Series B | 15M |
| 7/2005 | Centerre Healthcare Corporation | Venture Round | 30M |
| 10/2018 | CardiaLen | Series B | 17M |
| 11/2015 | Amplyx Pharmaceuticals | Series B | 40.5M |
| 11/2014 | Smart Wires | Series B | 18.4M |
| 10/2010 | IDEV Technologies | Series D | 46M |
| 10/2001 | NexRay | Venture Round | 21M |
| 2/2015 | Lyricpharma | Series A | 20.4M |
| 10/2000 | Salient Surgical Technologies | Series B | 0 |
| 10/2012 | ZS Pharma | Series C | 0 |
| 9/2005 | Kereos | Series B | 0 |
| 8/2016 | Tioma Therapeutics | Series A | 86M |
| 12/2017 | Allakos | Series B | 100M |
| 5/2013 | Lumena Pharmaceuticals | Series A | 23M |
| 1/2016 | Spruce Biosciences | Series A | 0 |
| 9/2004 | Velocimed | Series D | 0 |
| 1/2023 | Venture Med Group | Convertible Note | - |
| 1/2004 | Auxeris Therapeutics | Series A | 1.6M |
| 1/2019 | Good Therapeutics | Series A | 0 |
| 11/2021 | Venture Med Group | Convertible Note | - |
| 8/2011 | Securus Medical Group | Series A | 1.5M |
| 12/2021 | Good Therapeutics | Series B | 8M |
| 3/2014 | Lumena Pharmaceuticals | Series B | 45M |
| 2/2023 | Spruce Biosciences | Post-IPO Equity | 0 |
| 2/2020 | Spruce Biosciences | Series B | 88M |
| 6/2021 | Glycomine | Series B | 0 |
| 9/2003 | Conforma Therapeutics | Series C | 30M |
| 4/2020 | Avalyn Pharma | Series B | 35.5M |
| 1/2007 | Calypso Medical | Series D | 42.2M |
| 5/2019 | Reneo Pharmaceuticals | Series A | 50M |
| 2/2008 | Accumetrics | Series D | 0 |
| 6/2021 | Standard Bariatrics | Series B | 35M |
| 11/2007 | Excaliard Pharmaceuticals | Series A | 15.5M |
| 8/2010 | Otonomy | Series B | 38.5M |
| 5/2023 | OncoResponse | Venture Round | 0 |
| 4/2007 | Xoft | Series D | 0 |
| 5/2006 | MacroGenics | Series C | 45M |
| 4/2014 | Otonomy | Series D | 49M |
| 8/2017 | Amplyx Pharmaceuticals | Series C | 0 |
| 4/2018 | Standard Bariatrics | Series A | 0 |
| 8/2006 | Cabrellis Pharmaceuticals | Series A | 27.5M |
| 3/2014 | ZS Pharma | Series D | 0 |
| 3/2020 | Xilio Therapeutics | Series B | 100.5M |
| 1/2017 | Avalyn Pharma | Series A | 0 |
| 5/2017 | Genoa Pharmaceuticals | Series A | 62M |
| 9/2014 | Tryton Medical | Venture Round | 0 |
| 1/2010 | Salient Surgical Technologies | Venture Round | 15M |
| 9/2016 | Securus Medical Group | Series C | 0 |
| 11/2022 | Bonum | Series A | 93M |
| 8/2022 | Bluejay Therapeutics | Series B | 0 |
| 4/2021 | SeQure DX | Series A | 0 |
| 9/2010 | Tryton Medical | Series D | 20M |
| 8/2014 | Allakos | Series A | 24.5M |
| 11/2018 | Mirum Pharmaceuticals | Series A | 120M |
| 7/2021 | Wugen | Series B | 0 |
| 3/2021 | OncoResponse | Series C | 0 |
| 12/2021 | Good Therapeutics | Series B | 0 |
| 11/2021 | Venture Med Group | Convertible Note | - |
| 11/2021 | Biolinq | Series B | 0 |
| 10/2021 | Scout Bio | Series B | 0 |
| 7/2021 | Wugen | Series B | 0 |
| 6/2021 | Glycomine | Series B | 0 |
| 6/2021 | Standard Bariatrics | Series B | 0 |
| 5/2021 | Sparrow Pharmaceuticals | Series A | 0 |
| 4/2021 | Arch Oncology | Series C | 0 |
| 4/2021 | SeQure DX | Series A | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
